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Background: Many trials are evaluating therapies for men with metastatic hormone-
sensitive prostate cancer (mHSPC).
Objective: To systematically review trials of prostate radiotherapy.
Design, setting, and participants: Using a prospective framework (framework for
adaptive meta-analysis [FAME]), we prespeciﬁed methods before any trial results were
known. We searched extensively for eligible trials and asked investigators when results
would be available. We could then anticipate that a deﬁnitive meta-analysis of the
effects of prostate radiotherapy was possible. We obtained prepublication, unpublished,
and harmonised results from investigators.
Intervention: We included trials that randomised men to prostate radiotherapy and
androgen deprivation therapy (ADT) or ADT only.
Outcome measurements and statistical analysis: Hazard ratios (HRs) for the effects of
prostate radiotherapy on survival, progression-free survival (PFS), failure-free survival
(FFS), biochemical progression, and subgroup interactions were combined using
ﬁxed-effect meta-analysis.
Results and limitations: We identiﬁed one ongoing (PEACE-1) and two completed
(HORRAD and STAMPEDE) eligible trials. Pooled results of the latter (2126 men; 90%
of those eligible) showed no overall improvement in survival (HR = 0.92, 95% conﬁdence
interval [CI] 0.81–1.04, p = 0.195) or PFS (HR = 0.94, 95% CI 0.84–1.05, p = 0.238) with
prostate radiotherapy. There was an overall improvement in biochemical progression
(HR = 0.74, 95% CI 0.67–0.82, p = 0.94  108) and FFS (HR = 0.76, 95% CI 0.69–0.84,
p = 0.64  107), equivalent to 10% beneﬁt at 3 yr. The effect of prostate radiotherapyt second authors.
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varied by metastatic burden—a pattern consistent across trials and outcome
measures, including survival (<5, 5; interaction HR = 1.47, 95% CI 1.11–1.94,
p = 0.007). There was 7% improvement in 3-yr survival in men with fewer than ﬁve
bone metastases.
Conclusions: Prostate radiotherapy should be considered for men with mHSPC with a
low metastatic burden.
Patient summary: Prostate cancer that has spread to other parts of the body
(metastases) is usually treated with hormone therapy. In men with fewer than ﬁve
bone metastases, addition of prostate radiotherapy helped them live longer and
should be considered.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).
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Randomised controlled trials have evaluated, or are
currently evaluating, promising therapies for metastatic
hormone-sensitive prostate cancer (mHSPC), including
prostate radiotherapy [1,2]. Systematic reviews of these
trial results can help determine effective treatments, but are
usually planned after most trials have reported and focus on
published results. Consequently, their design and conduct
can be influenced by existing results, and they may not
include enough data to produce reliable findings.
A new framework for adaptive meta-analysis (FAME) [5]
defines review methods prospectively, prior to trial results
being published. It also helps anticipate emerging trial
results and identify the earliest opportunity for reliable
meta-analysis [6,7]. Results of the key trials investigating
prostate radiotherapy were due, which could provide
sufficient evidence about its effects.
2. Patients and methods
We aimed to assess the effects of adding prostate radiotherapy to
androgen deprivation therapy (ADT) in men with mHSPC. We
prespeciﬁed methods in a protocol prior to the results of eligible trials
being known (PROSPERO registration: CRD42018096108).
2.1. Treatment comparisons
Some eligible trials are assessing the effects of prostate radiotherapy
in conjunction with other agents. To allow for the possibility of an
interaction between these different treatments, we wanted to review the
effects of prostate radiotherapy, via two comparisons.
Comparison A: Prostate radiotherapy + ADT versus ADT
Comparison B: Prostate radiotherapy + other agent(s) + ADT versus
(same) other agents(s) + ADT
2.2. Framework for adaptive meta-analysis
We applied key FAME principles to: (1) start the systematic review
process whilst trials are ongoing or yet to report, (2) search
comprehensively for all eligible trials, (3) liaise with trial teams to
develop a detailed picture of these trials, (4) predict when sufﬁcient
results will be available for reliable meta-analysis, (5) conduct
meta-analysis and interpret results taking account of any unavailable
data, and (6) assess the value of updating.Please cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019),2.3. Trial eligibility
Randomised controlled trials were eligible if they randomised men with
mHSPC, starting or responding to ﬁrst-line hormone therapy, and
compared prostate radiotherapy plus ADT versus ADT. Trials including
additional agents (eg, docetaxel, abiraterone) were also eligible,
provided that the same additional agents were used in both treatment
and control arms. Trials were ineligible if they included men who
had stopped responding to ﬁrst-line hormone therapy, those with
castrate-refractory prostate cancer, or those in whom radiotherapy was
administered to metastases.
2.4. Trial identification
We regularly searched systematically for all published, unpublished, and
ongoing trials in mHSPC. With no language restrictions, we searched
MEDLINE, EMBASE, clinicaltrials.gov, and Cochrane CENTRAL up to June
2018 (see Supplementary material). We also searched relevant confer-
ence proceedings (Supplementary Table 1) and reference lists of review
articles, and identiﬁed trial reports/protocols.
Two reviewers independently assessed all unique records (L.H.R. and
S.B.), obtained full papers or protocols for any trials deemed potentially
eligible, and agreed on the ﬁnal set of trials. We asked trialists to
supplement this list, and provide updated status and reporting plans for
their trials.
2.5. Outcome measures
The primary outcome was survival, deﬁned as the time from
randomisation to death from any cause. Secondary outcomes were
progression-free survival (PFS), deﬁned as the time from randomisation
to ﬁrst symptomatic clinical or radiological progression or death
(excluding biochemical progression); biochemical progression, deﬁned
as the time from randomisation to ﬁrst biochemical (prostate-speciﬁc
antigen [PSA]) progression; and failure-free survival (FFS), deﬁned as the
time from randomisation to ﬁrst biochemical, clinical, or radiological
progression. We also aimed to describe acute toxicity on the
radiotherapy arm.
2.6. Data collection
We sought information from investigators on trial accrual period,
number of patients, age, PSA, performance status, T and N category,
location and number of metastases, disease history, Gleason sum score,
type of hormone therapy, volume of disease, prostate radiotherapy dose,
and toxicity. We also sought overall results for survival, PFS, FFS, and
biochemical progression according to our prespeciﬁed deﬁnitions, as
well as results for survival, PFS, and FFS by patient subgroups (age,therapy for Metastatic Hormone-sensitive Prostate Cancer: A
 https://doi.org/10.1016/j.eururo.2019.02.003
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type of hormone therapy, disease history, location of metastases, number
of bone metastases, and volume of disease by the CHAARTED [8] and
LATITUDE [9] deﬁnitions).
We assessed the risk of bias [10] of included trials based on sequence
generation, allocation concealment, completeness of outcome data, and
selective outcome reporting, using information obtained from trial
protocols, manuscripts, or investigators.
2.7. Analysis
2.7.1. Planning reliable meta-analyses
In early 2018, we identiﬁed three trials eligible for comparison A:
STAMPEDE [11], HORRAD [12], and PEACE-1 (NCT01957436; Table 1). We
found that the ongoing PEACE-1 trial was not due to report for some
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STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019), 2018. We anticipated that each would have a median follow-up of at least
3 yr and would provide results for 2140 men; 90% of those eligible. Based
on typical 3-yr survival in mHSPC [9,13], we predicted that these would
give approximately 66% and 99% power to detect 5% and 10% absolute
differences in 3-yr survival, respectively. Thus, we planned an early,
potentially deﬁnitive meta-analysis.
Two trials were eligible for comparison B: STAMPEDE [11] and
PEACE-1 (NCT01957436), potentially including 1299 men (Table 2).
However, as only the STAMPEDE results for 367 men randomised to
receive docetaxel as part of the standard of care were anticipated in 2018,
a deﬁnitive meta-analysis of comparison B is planned later.
2.7.2. Measuring treatment effects
For time-to-event outcome measures (overall survival, PFS, FFS, and
biochemical progression) and hazard ratios (HRs) were combined using
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acute bladder and bowel toxicities in the radiotherapy arm.
We also planned analyses of the effects of prostate radiotherapy on
overall survival by prespeciﬁed subgroups deﬁned by age (<70, >70 yr),
performance status (0, 1+), nodal status (N0, N+), Gleason sum score (<8,
8), type of ADT (orchiectomy, luteinising hormone-releasing hormone
[LHRH] agonist, LHRH antagonist), disease history (de novo metastatic
disease, relapsed after prior local therapy with curative intent), location of
metastases (bone, visceral, other), number of bone metastases (0, 1–3, 4–9,
>9), and volume of disease (high volume, low volume). If there were
insufﬁcient numbers of menwithin subgroups, we collapsedthem to achieve
groups of a reasonable size, or did not perform subgroup analyses. Where
categories were incompatible across trials or were not those predeﬁned for
the meta-analysis, we requested additional results from the investigators.
For each subgroup, we calculated interaction HRs separately for each
trial. For subgroups of two categories, interaction HRs were calculated as
the ratio of the two subgroup HRs. For subgroups of three ordered
categories, interaction HRs were estimated using a weighted linear
regression of subgroup HRs, with error variances assumed to be known.
The interaction HRs were combined across trials using a ﬁxed-effect
meta-analysis [16,17]. If there was any evidence of an interaction, we
replicated the relevant subgroup analysis on PFS and FFS, in order to
support or refute the ﬁndings. We subsequently estimated “pooled” HRs
by subgroup, consistent with the pooled interaction HR, using
multivariate meta-analysis with the variance estimated using the delta
method. Absolute differences in outcome at 3 yr were derived from these
subgroup HRs and a representative control-group event rate. All p values
are two sided. Analyses were carried out using [3] Stata version 15.1.[4]
2.7.3. Network meta-analysis of current therapies
Previously, we compared the relative effects of recent therapies
combined with ADT in a network meta-analysis [18]. If the survival
results of comparison A were deemed sufﬁciently reliable, we would
include them in an updated network meta-analysis.
3. Results
3.1. Characteristics of eligible trials
Our searches retrieved 19,830 unique records, and seven
mHSPC trials that were potentially eligible for comparison
A. Four trials were excluded: two because radiotherapy was
administered to metastases as well as the prostate ([19] and
NCT02913859), one because men did not receive ADT
(NCT02680587), and one because surgery or radiotherapy
was allowed as local treatment (NCT01751438), leaving
three eligible trials (Supplementary Fig. 1).
As the ongoing trial only closed to recruitment at the end
of 2018, the meta-analysis includes results of the two
completed and reported trials (HORRAD [12] and STAMPEDE
[11]). These include fewer men than anticipated (2126/2360),
because the number of individuals recruited to HORRAD was
fewer than planned (Table 1). but still represent about 90% of
men eligible for comparison A. (Table 1).
HORRAD randomised 432 men between 2004 and
2014, and STAMPEDE 1694 men between 2013 and 2016,
to prostate radiotherapy and ADT versus ADT (Table 3).
Median follow-up was 47 mo in HORRAD (interquartile
range [IQR]: 36–68 mo) and 41.9 mo in STAMPEDE (IQR:
31–49 mo).
All men were classified as having newly diagnosed
mHSPC and were receiving long-term ADT for the first time,Please cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019),mostly LHRH-based therapy (>99%). Across the two trials,
men were aged similarly (HORRAD, median age 67 yr;
STAMPEDE, median age 68 yr); most had World Health
Organisation/ECOG performance status 0 (HORRAD, 84%;
STAMPEDE, 71%) and a Gleason sum score of 8 (HORRAD,
66%; STAMPEDE, 79%). All men recruited to the HORRAD
trial had bone metastases, while 89% of men in the
STAMPEDE trial had bone metastases with (5%) or without
(84%) visceral metastases. As the HORRAD trial did not
collect data on nonbone metastases, it was not possible to
use the CHAARTED [8] or LATITUDE [9] trial definitions of
disease volume. However, the STAMPEDE team were able to
reclassify patients according to the HORRAD definition [20]
(low volume: Gleason sum score <9, fewer than five bone
lesions, and PSA 142; the HORRAD median). Few men in
the HORRAD trial (17%) had low-volume disease compared
with around half of the men in the STAMPEDE trial (45%).
In HORRAD, planned prostate radiotherapy was initially
70 Gy in 35 fractions over 7 wk (82%), with an alternative
schedule of 57.76 Gy in 19 fractions over 6 wk (12%) added
subsequently, which was considered biologically equivalent
to 70 Gy in 7 wk (6% unknown). In STAMPEDE, clinicians
had the choice of radiotherapy dose: 36 Gy in six fractions
over 6 wk (49%) or 55 Gy in 20 fractions over 4 wk (51%).
Based on randomisation sequence generation, allocation
concealment, completeness of outcome data, and selective
outcome reporting, both trials were judged to be at a low
risk of bias (Supplementary Table 2).
3.2. Overall treatment effects
Survival results are based on all 2126 men (969 deaths) from
HORRAD and STAMPEDE. Overall, there was no evidence
that the addition of prostate radiotherapy to ADT improved
survival (HR = 0.92, 95% confidence interval [CI] 0.81–1.04,
p = 0.195; heterogeneity chi-square = 0.08, degree of free-
dom = 1, p = 0.78; Fig. 1).
The PFS results based on all men (1305 events) also provided
no clear evidence that, overall, prostate radiotherapy extended
PFS (HR = 0.94, 95% CI 0.84–1.05, p = 0.238; Fig.1). Although, in
the HORRAD trial, biochemical progression was defined as the
time between diagnosis and a PSA increase after the initiation
of ADT of >50% of the lowest PSA value after the start of
treatment (with a minimum of 1 ng/ml), and in the STAMPEDE
trial as a rise above the lowest PSA within 24 wk of enrolment
of 50% to at least 4 ng/ml, we considered them sufficiently
compatible to combine. Based on all men and 1533 events, we
observed a highly statistically significant benefit of prostate
radiotherapy (HR = 0.74, 95% CI 0.67–0.82, p = 0.94  108;
Fig. 1) in biochemical progression, which translates to an
absolute improvement of 11 (7–14)% at 3 yr from 25% to 36%.
The FFS results based on all men (1662 events) were very
similar (HR = 0.76, 95% CI 0.69–0.84, p = 0.64  107; Fig. 1).
Toxicity results are not yet available for HORRAD. Based
on the results collected from STAMPEDE, 4% of men who
received prostate radiotherapy had severe acute bladder
toxicity, and 1% had severe acute bowel toxicity (RTOG
scale). Reported STAMPEDE results showed that 4% of men
had severe late effects.therapy for Metastatic Hormone-sensitive Prostate Cancer: A
 https://doi.org/10.1016/j.eururo.2019.02.003
Table 3 – Characteristics of patients at randomisation
HORRAD [11] STAMPEDE [12] a
ADT RT + ADT ADT RT + ADT
Number of patients 216 216 845 849
Disease history
Newly diagnosed M1 216 (100) 216 (100) 845 (100) 849 (100)
Type of ADT, n (%)
Orchiectomy 4 (2) 1 (<1) 0 0
LHRH agonist 212 (98) 210 (97) 672 (80) 684 (81)
LHRH antagonist 0 0 165 (19) 159 (18)
Missing 0 5 (2) 8 (1) 6 (<1)
Time from initial diagnosis (mo), n (%)
Median (IQR) <1 (2–5 wk) <1 (2–6 wk) 2.4 (1.8–3.1) 2.4 (1.8, 3.1)
Range 0–42 0–25 0–114.8 0–41.9
Missing 0 0 5 14
Time to ADT start (wk)
Median (IQR) 1 (3, 0) 1 (3, 0) 1.7 (2.3, 1.1) 1.7 (2.3, 1.1)
Range 17 to 2 13 to 2 2.8 to 1.1 2.8 to 0.3
Missing 2 4 0 1
Age (yr)
Median (IQR) 67 (61–71) 67 (62–71) 68 (63, 73) 68 (63, 73)
Range 47–85 47–79 37–84 45–87
WHO/ECOG performance status
0 176 (82) 187 (87) 597 (71) 603 (71)
1+ 40 (18) 29 (13) 248 (29) 246 (29)
PSA (ng/ml), n (%)
Median (IQR) 149 (50–483) 125 (48–433) 100 (30, 311) 96 (33,299)
Range 4–6991 8–14,000 1–20,590 1–11,156
T category
T0 0 0 0 2 (<1)
T1 5 (2) 7 (3) 11 (1) 11 (1)
T2 20 (10) 33 (15) 69 (8) 73 (9)
T3 128 (59) 125 (58) 474 (56) 500 (59)
T4 59 (27) 51 (24) 222 (26) 198 (23)
Tx 4 (2) 0 69 (9) 65 (7)
N category, n (%)
N0 – – 293 (35) 292 (34)
N+ – – 500 (59) 498 (59)
Nx 216 (100) 216 (100) 52 (6) 59 (7)
Gleason sum score, n (%)
<8 71 (33) 73 (34) 151 (18) 144 (17)
8 144 (66) 142 (65) 668 (79) 665 (78)
Unknown 1 (<1) 1 (<1) 26 (3) 40 (5)
Number of bone metastases, n (%)
<5 71 (33) 89 (41) 404 (48) 399 (47)
>5 145 (67) 127 (58) 397 (47) 393 (46)
Unknown – – 44 (5) 57 (7)
Metastatic burden (HORRAD deﬁnitionb), n (%)
Low burden 35 (16) 39 (18) 385 (46) 387 (46)
High burden 181 (84) 177 (82) 416 (49) 405 (48)
Unknown – – 44 (5) 57 (6)
Planned RT dose, n (%)
36 Gy in 6 fr over 6 wk, n (%) NA NA NA 416 (49)
55 Gy in 20 fr over 4 wk n (%) NA NA NA 433 (51)
70 Gy in 35 fr over 7 wk, n (%) NA 176 (82) NA NA
57.76 Gy in 19 fr over 4 wk, n (%) NA 26 (12) NA NA
Unknown, n (%) 14 (6)
ADT = androgen deprivation therapy; fr = fraction; IQR = interquartile range; LHRH = luteinising hormone-releasing hormone; NA = not available;
RT = radiotherapy.
a Based on the participants who did not receive docetaxel as part of standard of care.
b Low = Gleason sum score <9 and <5 bone lesions and PSA <142 (HORRAD median).
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367 men, the STAMPEDE survival results for men planned
for docetaxel (HR = 0.81, 95% CI 0.49–1.34, p = 0.379) were
broadly similar to the results of comparison A.Please cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019), 3.3. Treatment effects by patient characteristics
As all men were newly diagnosed and most received LHRH-
based ADT; planned survival analyses by disease history andtherapy for Metastatic Hormone-sensitive Prostate Cancer: A
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Fig. 1 – Effect of adding prostate radiotherapy to ADT on (A) survival, (B) progression-free survival, (C) biochemical progression, and (D) failure-free
survival in men with mHSPC. Each filled square denotes the HR for that trial comparison, with the horizontal lines showing the 95% confidence
interval (CI). The size of the square is directly proportional to the amount of information contributed by a trial. The diamond represents a
(fixed-effect) meta-analysis of the trial HRs, with the centre of this diamond indicating the HR and the extremities the 95% CI. ADT = androgen
deprivation therapy; HR = hazard ratio; RT = radiotherapy.
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the effect of prostate radiotherapy on survival varied by our
prespecified subgroups: age (interaction HR = 0.89, 95% CI
0.68–1.15, p = 0.367), performance status (interaction
HR = 1.05, 95% CI 0.79–1.40, p = 0.712), clinical T-stage
(interaction HR = 1.09, 95% CI 0.88–1.35, p = 0.447), and
Gleason sum score (interaction HR = 0.85, 95% CI 0.61–1.20,
p = 0.354; Fig. 2).
As the HORRAD trial collected the number of bone
metastases in three prespecified categories (<5, 5–15, and
>15), and the STAMPEDE trial collected the absolute
number of metastases up to 9 and then >9, we obtained
compatible results from both trials for our planned analyses
(<5, 5). The effect of prostate radiotherapy on survival
varied by the number of bone metastases (interaction
HR = 1.47, 95% CI 1.11–1.94, p = 0.007; Fig. 3), with a benefit
seen in men with fewer than five bone metastasesPlease cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019),(HR = 0.73, 95% CI 0.58–0.92, p = 0.0071), which translates
to an absolute improvement of 7% (95% CI 2–11%) at 3-yr
survival (from 70% to 77%). There was no clear evidence of
an effect among men with five or more bone metastases
(HR = 1.07, 95% CI 0.92–1.26, p = 0.37). A similar planned
analysis of PFS (interaction HR = 1.32, 95% CI 1.04–1.67,
p = 0.021; Fig. 3) and an exploratory analysis of FFS
(interaction HR = 1.35, 95% CI 1.10–1.66, p = 0.004; Fig. 3)
gave comparable results.
An exploratory analysis using the HORRAD definition
[20] provided evidence that the effect of prostate radio-
therapy on survival varied by volume of disease (interaction
HR = 1.44, 95% CI 1.07–1.95, p = 0.017; Supplementary
Fig. 2), which was supported by similar analyses of PFS
(HR = 1.28, 95% CI 1.00–1.64, p = 0.054; Supplementary
Fig. 2) and FFS (HR = 1.40, 95% CI 1.12–1.74, p = 0.003;
Supplementary Fig. 2).therapy for Metastatic Hormone-sensitive Prostate Cancer: A
 https://doi.org/10.1016/j.eururo.2019.02.003
Fig. 2 – Effect of adding prostate radiotherapy to ADT on survival by patient age at randomisation, performance status, clinical T stage, and Gleason
sum score. Each filled square denotes the HR for each subgroup of men defined by, age at randomisation, performance status, clinical T stage, and
Gleason sum score within each trial, with the horizontal lines showing the 95% confidence interval (CI). The size of the square is directly proportional
to the amount of information contributed by a subgroup. Each filled circle denotes the HR for the interaction between the effect of radiotherapy and
these subgroups for each trial, with the horizontal lines showing the 95% CI. The size of each circle is directly proportional to the amount of
information contributed by a trial. The open circle represents a (fixed-effect) meta-analysis of the interaction HRs, with the horizontal line showing
the 95% CI. ADT = androgen deprivation therapy; HR = hazard ratio; RT = radiotherapy.
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As the effect of prostate radiotherapy on survival was
influenced by metastatic burden, this would need to be
accounted for in the planned update of the network
meta-analysis of recent therapies for mHSPC [18], and such
methods are still in development [21]. It would also require
the collection and analysis of individual participant data
(IPD) from all trials.
4. Discussion
4.1. Summary of results
Prostate radiotherapy did not clearly improve survival or
PFS in unselected men with mHSPC. However, there was aPlease cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019), clear difference in the effect by metastatic burden on
survival, with an absolute improvement of 7% in 3-yr
survival in men who had four or fewer bone metastases.
There was no evidence that the effect of prostate
radiotherapy on survival varied by other patient or disease
characteristics. Prostate radiotherapy improved 3-yr
biochemical progression and FFS by 10% in unselected
men, but the size of effect varied by metastatic burden.
4.2. Strengths
Based on 90% of all men randomised to prostate radiother-
apy plus ADT versus ADT, we have shown that the effect of
prostate radiotherapy on survival varies by metastatic
burden. Despite different recruitment periods, radiotherapytherapy for Metastatic Hormone-sensitive Prostate Cancer: A
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Fig. 3 – Effect of adding prostate radiotherapy to ADT on survival, progression-free survival, and failure-free survival (exploratory) by the number of
bone metastases. ADT = androgen deprivation therapy; HR = hazard ratio; RT = radiotherapy.
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metastatic burdens, this pattern was remarkably and
reassuringly consistent across trials and outcomes. As a
prospectively designed FAME review, all methods were
published (unless otherwise specified) before trial results
were known. This includes the preplanned subgroup
analyses by metastatic burden, albeit that we had to
collapse subgroup categories. We were able to anticipate
when the results of STAMPEDE and HORRAD were due,
allowing us to align the review with publication of their
results [11,12]. By obtaining unpublished trial results, we
could harmonise outcome and subgroup definitions and
conduct additional analyses. Hence, we have been able to
provide a more timely, reliable, and thorough synthesis of
the effects of prostate radiotherapy than is usually possible
with summary results [5].
4.3. Limitations
Only two of the relevant trials are included, but the
234 eligible men from the recently completed PEACE-1 trial
(Table 1) represent just 10% of the total, and so its results are
unlikely to materially affect our findings. While the
STAMPEDE trial heavily influences the results, the HORRAD
trial has longer follow-up and adds considerable weight to
the analyses of all outcome measures (23–28%; Fig. 1),
including the survival analysis by metastatic burden (25%;
Fig. 3). Therefore, until internationally agreed, optimisedPlease cite this article in press as: Burdett S, et al. Prostate Radio
STOPCAP Systematic Review and Meta-analysis. Eur Urol (2019),definitions of the metastatic burden and the oligometastatic
state are determined [22], the number of bone metastases
alone could help identify groups of men who might benefit
from prostate radiotherapy.
4.4. Context
Results from PEACE-1 in combination with the current
results of STAMPEDE will provide the first substantive
evidence of how prostate radiotherapy works in conjunc-
tion with docetaxel and/or abiraterone. A new trial (SWOG
S1802, NCT03678025) of standard systemic therapy with or
without definitive treatment (surgery or radiotherapy)
may also contribute to this comparison, if it stratifies
by definitive treatment. Three trials (TROMBONE [ISRCTN
15704862], g-RAMPP [NCT02454543], and SIMCAP
[NCT03456843]) are investigating whether radical prosta-
tectomy offers an alternative to radical radiotherapy in this
setting, and two trials [19] (NCT02913859) and a new
STAMPEDE arm are evaluating the effects of administering
radiotherapy to metastatic sites as well as the prostate.
4.5. Implications
The collection of IPD from relevant trials could help
determine which men with mHSPC benefit more or less
from prostate radiotherapy and what the optimal definition
of metastatic burden might be. A comprehensive repositorytherapy for Metastatic Hormone-sensitive Prostate Cancer: A
 https://doi.org/10.1016/j.eururo.2019.02.003
E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X – X X X 9
EURURO-8268; No. of Pages 10of IPD from all modern mHSPC trials (STOPCAP M1 IPD
repository) is being established with funding from MRC and
Prostate Cancer UK to tackle these and other important
clinical uncertainties (http://www.stopcapm1.org/). How-
ever, applying the review findings in settings where newer
imaging techniques (eg, prostate-specific membrane anti-
gen positron emission tomography) are available could be
problematic, as men currently classed as having a low
metastatic burden may be reclassified as having a greater
number of metastases. Questions also remain regarding the
timing and optimal dose of radiotherapy.
5. Conclusions
The addition of prostate radiotherapy to ADT should be
considered for men with mHSPC who have four or fewer
bone metastases.
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